Thank you Nasdaq for shinning a light today on Adaptive Phage Therapeutics and the significant market potential of our phage therapy in meeting the rapidly expanding un-met need for a cure for patients with antibiotic resistant bacterial infections. Thanks to the NEXT team at Shulman Rogers for your support!
{iframe}https://www.linkedin.com/posts/greg-merril-11aab31_nasdaq-biotech-shulmanrogers-activity-6590738046444990464-C7Jb/{/iframe}